AZ notches another win in cancer with Tagrisso in NSCLC

AstraZeneca continued its momentum of positive cancer news this summer as Tagrisso osimertinib showed a survival benefit in first-line NSCLC.

AstraZeneca plc (LSE:AZN; NYSE:AZN) said the oral irreversible inhibitor of EGFR activating mutations significantly improved overall survival (OS), a secondary endpoint, in the Phase III FLAURA trial as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR mutations...